Oligomeric Proanthocyanidins (OPCs) from Grape Seed Extract Suppress the Activity of ABC Transporters in Overcoming Chemoresistance in Colorectal Cancer Cells

Overview

Journal Carcinogenesis

Specialty Oncology

Date 2019 Jan 1

PMID 30596962

Citations 18

Authors

Preethi Ravindranathan

Divya Pasham

Ajay Goel

Affiliations

Soon will be listed here.

Abstract

Multidrug resistance is a major hindrance in managing cancer. By performing a series of experiments in chemoresistant colorectal cancer cell lines, we demonstrate that oligomeric proanthocyanidins (OPCs) from grape seed extracts can sensitize both acquired (HCT116-FOr cells) and innately chemoresistant (H716 cells) cancer cells to chemotherapeutic drugs, 5-fluorouracil (5FU) and oxaliplatin, by inhibiting adenosine triphosphate-binding cassette (ABC) transporter proteins. When combined with chemotherapeutic drugs, OPCs significantly inhibited growth of the chemoresistant cells (P < 0.05 to < 0.001) and decreased the expression of several key ABC transporters. Moreover, the activity of the ABC transporters was also significantly decreased by OPCs in the cell lines (P < 0.05). We further confirmed that co-treatment with OPCs sensitized the chemoresistant cells to 5FU and oxaliplatin, as observed by improvement in cell cycle arrest, double-strand breaks and p53 accumulation in these cells. In addition, we confirmed that co-administration of OPCs with chemotherapeutic drugs significantly decreased chemoresistant xenograft tumor growth in mice (P < 0.05). Together, our study illuminates the downregulation of multiple ABC transporters as a mechanism by which OPCs overcome chemoresistance in cancer cells and may serve as adjunctive treatments in patients with refractory colorectal cancer.

Citing Articles

Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer.

Haynes J, Manogaran P Int J Mol Sci. 2025; 26(5).

PMID: 40076613 PMC: 11901061. DOI: 10.3390/ijms26051988.

A comprehensive update on the potential of curcumin to enhance chemosensitivity in colorectal cancer.

Shadnoush M, Momenan M, Seidel V, Tierling S, Fatemi N, Nazemalhosseini-Mojarad E Pharmacol Rep. 2024; 77(1):103-123.

PMID: 39304638 DOI: 10.1007/s43440-024-00652-y.

Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling.

Albadari N, Xie Y, Li W Front Pharmacol. 2024; 14:1340401.

PMID: 38269272 PMC: 10806212. DOI: 10.3389/fphar.2023.1340401.

Antiproliferative and Apoptosis Effects of Hybrid Varieties of Vitis vinifera L. Sweet Sapphire and Sweet Surprise on Human Prostate Cancer Cells Using In Vitro and In Silico Approaches.

Cruz M, Pascoal G, Jacintho M, Wagner M, Coimbra P, Araujo-Lima C Asian Pac J Cancer Prev. 2023; 24(11):3673-3684.

PMID: 38019224 PMC: 10772743. DOI: 10.31557/APJCP.2023.24.11.3673.

The Role of ATP-Binding Cassette Subfamily A in Colorectal Cancer Progression and Resistance.

Alketbi L, Al-Ali A, Talaat I, Hamid Q, Bajbouj K Int J Mol Sci. 2023; 24(2).

PMID: 36674859 PMC: 9860967. DOI: 10.3390/ijms24021344.

References

Kastan M, Onyekwere O, Sidransky D, Vogelstein B, Craig R . Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991; 51(23 Pt 1):6304-11. View

Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B . The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett. 2003; 140-141:133-43. DOI: 10.1016/s0378-4274(02)00497-6. View

Seiden M, Swenerton K, Matulonis U, Campos S, Rose P, Batist G . A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol. 2002; 86(3):302-10. DOI: 10.1006/gyno.2002.6762. View

Modok S, Mellor H, Callaghan R . Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol. 2006; 6(4):350-4. DOI: 10.1016/j.coph.2006.01.009. View

Herraez E, Sanchez-Vicente L, Macias R, Briz O, Marin J . Usefulness of the MRP2 promoter to overcome the chemoresistance of gastrointestinal and liver tumors by enhancing the expression of the drug transporter OATP1B1. Oncotarget. 2017; 8(21):34617-34629. PMC: 5470996. DOI: 10.18632/oncotarget.16119. View

Robey R, Pluchino K, Hall M, Fojo A, Bates S, Gottesman M . Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018; 18(7):452-464. PMC: 6622180. DOI: 10.1038/s41568-018-0005-8. View

Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

Nile S, Park S . Edible berries: bioactive components and their effect on human health. Nutrition. 2013; 30(2):134-44. DOI: 10.1016/j.nut.2013.04.007. View

Gollucke A, Aguiar Jr O, Barbisan L, Ribeiro D . Use of grape polyphenols against carcinogenesis: putative molecular mechanisms of action using in vitro and in vivo test systems. J Med Food. 2013; 16(3):199-205. DOI: 10.1089/jmf.2012.0170. View

10.

Kelly R, Draper D, Chen C, Robey R, Figg W, Piekarz R . A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res. 2010; 17(3):569-80. PMC: 3071989. DOI: 10.1158/1078-0432.CCR-10-1725. View

11.

Baer M, George S, Dodge R, OLoughlin K, Minderman H, Caligiuri M . Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002; 100(4):1224-32. View

12.

Abdullah L, Chow E . Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013; 2(1):3. PMC: 3565873. DOI: 10.1186/2001-1326-2-3. View

13.

Lowe S, Ruley H . Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 1993; 7(4):535-45. DOI: 10.1101/gad.7.4.535. View

14.

Keogh J . Membrane transporters in drug development. Adv Pharmacol. 2012; 63:1-42. DOI: 10.1016/B978-0-12-398339-8.00001-X. View

15.

Kamata S, Kishimoto T, Kobayashi S, Miyazaki M . Expression and localization of ATP binding cassette (ABC) family of drug transporters in gastric hepatoid adenocarcinomas. Histopathology. 2008; 52(6):747-54. DOI: 10.1111/j.1365-2559.2008.03026.x. View

16.

Yamasaki M, Makino T, Masuzawa T, Kurokawa Y, Miyata H, Takiguchi S . Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer. 2011; 104(4):707-13. PMC: 3049584. DOI: 10.1038/sj.bjc.6606071. View

17.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

18.

Gandhi L, Harding M, Neubauer M, Langer C, Moore M, Ross H . A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer. 2007; 109(5):924-32. DOI: 10.1002/cncr.22492. View

19.

Ferry D, Traunecker H, Kerr D . Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer. 1996; 32A(6):1070-81. DOI: 10.1016/0959-8049(96)00091-3. View

20.

Friedenberg W, Rue M, Blood E, Dalton W, Shustik C, Larson R . Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology.... Cancer. 2006; 106(4):830-8. DOI: 10.1002/cncr.21666. View